Research Topics
| Michael A BookmanSummaryAffiliation: Fox Chase Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinicM A Bookman
Division of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Int J Gynecol Cancer 15:12-7. 2005..Integration of dFdC with platinum and/or radiation should also be investigated...- Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5M A Bookman
Division of Medical Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Gynecol Cancer 13:149-55. 2003..Results from GOG158 will be reviewed, including an analysis of second-look surgical outcomes, followed by an update on the current status of GOG0182-ICON5... - Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5M A Bookman
Division of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Int J Gynecol Cancer 13:735-40. 2003..Results from GOG158 will be reviewed, including an analysis of second-look surgical outcomes, followed by an update on the current status of GOG0182-ICON5... - Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182)Michael A Bookman
Division of Medical Science, Fox Chase Cancer Center, Philadelphia, PA 19046, USA
Semin Oncol 29:20-31. 2002..The selection of candidate regimens for this trial illustrates the challenges of drug development in EOC... - Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology GroupM A Bookman
Division of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
Int J Gynecol Cancer 11:42-51. 2001..The selection of candidate regimens for this trial illustrate the challenges of drug development in EOC... - Using tumor registry resources in analyzing concordance with guidelines and outcomesM A Bookman
Division of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
Oncology (Williston Park) 14:104-7. 2000..One strategy that can be used to facilitate a global outcomes program within the NCCN community calls for capitalizing on existing local database resources and experienced coding and data management staff... - Developmental chemotherapy and management of recurrent ovarian cancerMichael A Bookman
Fox Chase Cancer Center, Philadelphia, PA 19111, USA
J Clin Oncol 21:149s-167s. 2003.... - Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapyM A Bookman
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Oncologist 4:87-94. 1999..Early use of topotecan offers an effective and tolerable strategy that can prolong the platinum-free interval and optimize subsequent retreatment with platinum... - Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxelM A Bookman
Fox Chase Cancer Center, Department of Medical Oncology, Philadelphia, PA 19111, USA
J Clin Oncol 16:3345-52. 1998..Topotecan, a topoisomerase I inhibitor, was evaluated in a multicenter, phase II study of women with epithelial ovarian carcinoma who relapsed after one or two prior regimens that included platinum and paclitaxel... - Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology GroupMichael A Bookman
Division of Medical Science, Fox Chase Cancer Center, Rockledge, PA, USA
J Clin Oncol 21:283-90. 2003..To evaluate the feasibility, toxicity, and efficacy of single-agent monoclonal antibody therapy targeting the human epidermal growth factor receptor 2 (HER2)/neu receptor in ovarian and primary peritoneal carcinoma... - Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer IntergroupMichael A Bookman
Fox Chase Cancer Center, Philadelphia, PA 19111, USA
J Clin Oncol 27:1419-25. 2009.... - Incorporation of bevacizumab in the primary treatment of ovarian cancerRobert A Burger
Fox Chase Cancer Center, Philadelphia, PA 19111, USA
N Engl J Med 365:2473-83. 2011..Bevacizumab, a humanized anti-vascular endothelial growth factor monoclonal antibody, has shown single-agent activity in women with recurrent tumors. Thus, we aimed to evaluate the addition of bevacizumab to standard front-line therapy... - Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology GroupMark A Morgan
Section of Gynecologic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
Gynecol Oncol 110:329-35. 2008.... - Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapyR J Schilder
Fox Chase Cancer Center, Philadelphia, PA, USA
J Clin Oncol 19:1183-94. 2001..This approach remains experimental and should be used only in the context of a clinical trial... - Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology GroupMichael A Bookman
Division of Medical Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Gynecol Oncol 103:473-8. 2006..Selection of a feasible sequence and schedule of carboplatin in combination with topotecan for evaluation in advanced epithelial ovarian cancer (EOC)... - Is there still a role for hormonal therapy?M A Bookman
Division of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Int J Gynecol Cancer 15:291-7. 2005..As such, it is reasonable to consider a number of potential hormonal interventions related to the prevention and treatment of ovarian cancer... - Standard treatment in advanced ovarian cancer in 2005: the state of the artM A Bookman
Division of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Int J Gynecol Cancer 15:212-20. 2005..While not an exhaustive review, this study will focus on key clinical concepts that are guiding ovarian cancer research and treatment... - First-line randomized trials: revisiting the Ptolemaic universeM A Bookman
Division of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Int J Gynecol Cancer 18:47-52. 2008..Rapid developments in molecular-targeted therapy are challenging our paradigm for future clinical trials, and our priorities need to be carefully considered... - Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cellsR J Schilder
Fox Chase Cancer Center, Philadelphia, PA 19111, USA
J Clin Oncol 17:2198-207. 1999..To determine the safety and feasibility of delivering multiple cycles of front-line high-dose carboplatin and paclitaxel with hematopoietic peripheral-blood stem cell (PBSC) support... - Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: A Gynecologic Oncology Group studyBunja Rungruang
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Magee Womens Hospital of UPMC, Pittsburgh, PA, USA
Gynecol Oncol 124:53-8. 2012..To examine whether clinical outcomes varied with intraperitoneal (IP) and/or retroperitoneal (RP) involvement in stage IIIC epithelial ovarian cancer (EOC) patients with microscopic residual disease after cytoreduction... - Focus on epithelial ovarian cancerRobert F Ozols
Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Cancer Cell 5:19-24. 2004 - Selecting high priority quality measures for breast cancer quality improvementMichael J Hassett
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Med Care 46:762-70. 2008..We sought to develop a simple, explicit strategy for prioritizing breast cancer quality measures based on their potential to highlight areas where quality improvement efforts could most impact a population... - Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administrationG P Adams
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Cancer Immunol Immunother 40:299-306. 1995..06 microgram/ml, at the 48-h point. These results suggest that multiple high-dose administrations of radiolabeled 741F8 (sFv')2 may lead to the selective tumor localization of therapeutic radiation doses... - Speeding up the evaluation of new agents in cancerMahesh K B Parmar
Clinical Trials Unit, London, UK
J Natl Cancer Inst 100:1204-14. 2008..By using intermediate outcomes and testing a number of new agents (and combinations) simultaneously, the new design requires fewer patients. Three trials using this methodology are presented... - A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group studyDeborah K Armstrong
Johns Hopkins Kimmel Cancer Center, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231 1000, USA
Gynecol Oncol 105:667-71. 2007.... - Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxelRobert F Ozols
Gynecol Oncol 103:1-6. 2006 - Progress in the management of gynecologic cancer: consensus summary statementStephen A Cannistra
Department of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital, Boston, USA
J Clin Oncol 21:129s-132s. 2003 - Phase I escalation of gemcitabine combined with protracted oral etoposide in gynecologic malignancies: A Gynecologic Oncology Group studyAgustin A Garcia
Division of Medical Oncology, University of Southern California Norrris Comprehensive Cancer Center, Los Angeles 90089, USA
Invest New Drugs 20:383-7. 2002..This, combined with preclinical synergism, prompted the Gynecologic Oncology Group to determine the maximum tolerated dose (MTD) of this combination... - Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group studyKatherine Y Look
Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
Gynecol Oncol 92:93-100. 2004.... - Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group studySteven C Plaxe
Department of Gynecologic Oncology, University of California at San Diego, San Diego, California 92103, USA
Gynecol Oncol 84:32-5. 2002..Due to its unique mechanism of action and preclinical activity against hypoxic and noncycling cells, PZA should be considered for evaluation in combination with other active agents... - Intraperitoneal chemotherapy for ovarian cancerRobert F Ozols
N Engl J Med 354:1641-3; author reply 1641-3. 2006 - The use of radiation as a component of breast conservation therapy in National Comprehensive Cancer Network CentersThomas A Buchholz
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 24:361-9. 2006..We investigated rates of radiation use after breast conservation therapy (BCT) for patients treated for ductal carcinoma-in-situ (DCIS) or invasive breast cancer at National Comprehensive Cancer Network (NCCN) centers... - Cervical cancerBenjamin E Greer
J Natl Compr Canc Netw 6:14-36. 2008 - A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumorsJames A Posey
Departments of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294 3300, USA
Clin Cancer Res 8:3092-9. 2002..024 to 0.962 mg/m(2), administered on days 1, 4, 8, and 11, followed by 2 weeks of rest and a second cycle of therapy. Pharmacokinetics and human antibody response to SGN-10 were also determined... - Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centersStephen B Edge
Roswell Park Cancer Institute, Buffalo, NY 14263, USA
J Natl Cancer Inst 95:1514-21. 2003..This study examined the extent and time trends of the use of SNB in stage I and II breast cancer patients... - Uterine cancersBenjamin E Greer
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA, USA
J Natl Compr Canc Netw 4:438-62. 2006